Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

WEEKLY ORAL ISLATRAVIR PROVIDES EFFECTIVE PEP AGAINST IV CHALLENGE WITH SIVMAC251

By Jimmy He PharmD, DScApril 28, 2020

…that a single low oral dose given within 24 hours of HIV exposure may provide effective PEP. These results support the potential utility of ISL as a simplified PEP agent….

1342 – Patterns of PrEP Use Among Rural South Africa Youth Given Choice: Process Data From the LAPIS Trial

By Jimmy He PharmD, DScMarch 20, 2025

…women), 55/359 (15.3%) chose oral PrEP (29 women), and 28/359 (7.8%) chose PEP (14 women). None chose the dapivarine ring.  At enrolment, 88/315 (27.9%) had an STI (gonorrhoea or chlamydia)….

Irreversible inactivation and breakdown of HIV1 with Env-gp120 targeting peptide triazole thiols

By Enthusiast Inc MDSeptember 29, 2014

…cell-free virions, leading to virus core release. We seek to understand the mechanism of this cell-free virolysis. We hypothesize that the PT-SH hijacks the viral fusion mechanism prior to cell…

Early Adopters: Correlates of Chemoprophylaxis Use in an Online Sample of US Men Who Have Sex With Men

By Enthusiast Inc MDSeptember 29, 2014

Background: Although HIV pre-exposure prophylaxis (PrEP) use has been shown to decrease HIVincidence among men who have sex with men (MSM), uptake has not been widespread, and the demographics and…

E/C/F/TAF SINGLE TABLET REGIMEN FOR HIV POSTEXPOSURE PROPHYLAXIS

By Enthusiast Inc MDMarch 7, 2019

…were observed. PEP E/C/F/TAF was well tolerated and demonstrated good completion rates. Self-reported and drug levels indicated good adherence, confirming that E/C/F/TAF could be a regimen of choice for PEP….

1131 – Addressing Advanced HIV Disease: Insights on CD4 Testing and AHD Prevalence at PEPFAR Sites

By Jimmy He PharmD, DScMarch 20, 2025

…study evaluated CD4 testing coverage and AHD prevalence at U.S. Agency for International Development (USAID) sites supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Methods The PEPFAR…

Treatment Interruption Patterns Among Young People in USAID-Supported PEPFAR Programs

By Jimmy He PharmD, DScMarch 6, 2024

…viral load and onward HIV transmission. To better understand continuity of treatment, we analyzed treatment interruption patterns among children, adolescents, and young adults in USAID-supported PEPFAR countries. Methods: Routinely collected…

200 – Ensitrelvir to Prevent COVID-19 in Households: SCORPIO-PEP Phase III Placebo-Controlled Trial Results

By Jimmy He PharmD, DScMarch 20, 2025

…household contacts (HHC) of index patients (IP) with COVID-19. Methods SCORPIO-PEP was a double-blind, placebo-controlled trial in HHC of IP with laboratory-confirmed COVID-19 conducted in the US, Japan, and other…

Significant Intolerability of Efavirenz in HIV Occupational Postexposure Prophylaxis

By Enthusiast Inc MDFebruary 27, 2015

…NRTIs + EFV regimen was significantly associated with premature discontinuation of occupational PEP. This regimen should not be further used for HIV prophylaxis following occupational exposure in the resource-limited settings….

Significant Intolerability of Efavirenz in HIV Occupational Postexposure Prophylaxis

By Enthusiast Inc MDFebruary 27, 2015

…NRTIs + EFV regimen was significantly associated with premature discontinuation of occupational PEP. This regimen should not be further used for HIV prophylaxis following occupational exposure in the resource-limited settings….

←1
2345678910
…1112131415…
16171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top